The pharmaceutical company Novo Nordisk will be responsible for marketing the oral presentation of Wegovy (semaglutide 25 mg) in Spain, the first treatment of its kind for weight loss and obesity management.
Wegovy will be marketed in Spain without public funding, at a cost of €236.20 for a…
Read More...